Portal de Periódicos da CAPES

Fentanyl pectin nasal spray for breakthrough cancer pain

2015; Mark Allen Group; Volume: 21; Issue: 3 Linguagem: Inglês

10.12968/ijpn.2015.21.3.114

2052-286X

L. M. Torres, José Manuel Trinidad, Enrique J. Calderón, Diego S. Benítez, Michael Perelman,

Pharmacological Effects and Toxicity Studies

International Journal of Palliative NursingVol. 21, No. 3 CommentaryFentanyl pectin nasal spray for breakthrough cancer painLuis M Torres, Jose M Trinidad, Enrique Calderón, Diego Benitez, Michael PerelmanLuis M TorresSearch for more papers by this author, Jose M TrinidadSearch for more papers by this author, Enrique CalderónSearch for more papers by this author, Diego BenitezSearch for more papers by this author, Michael PerelmanSearch for more papers by this authorLuis M Torres; Jose M Trinidad; Enrique Calderón; Diego Benitez; Michael PerelmanPublished Online:27 Mar 2015https://doi.org/10.12968/ijpn.2015.21.3.114AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article References Abernethy AP, Wheeler JL, Fortner BV (2008) A health economic model of breakthrough pain. Am J Manag Care 14(5 Suppl 1): S129–40 Medline, Google ScholarBennett D, Burton AW, Fishman S et al. (2005) Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2 management. Pharmacy and Therapeutics 30(6): 354−61 Google ScholarCaraceni A, Bertetto O, Labianca R et al. (2012a) Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain. J Pain Symptom Manage 43(5): 833–41 Crossref, Medline, Google ScholarCaraceni A, Hanks G, Kaasa A et al. (2012b) Use of Opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EPAC. Lancet Oncol 13(2): e58–68 Crossref, Medline, Google ScholarCastille J, Cheng YH, Simmons B et al. (2013) Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip. Drug Development & Industrial Pharmacy 39(5): 816–24 Crossref, Medline, Google ScholarDavies AN, Dickman A, Reid C et al. (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13(4): 331–8 Crossref, Medline, Google ScholarDavies A, Zeppetella G, Andersen S et al. (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15(7): 756–63 Crossref, Medline, Google ScholarDavies A, Sitte T, Elsner F et al. (2011) Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 41(2):358–66 Crossref, Medline, Google ScholarFallon M, Reale C, Davies A et al. (2011) Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of break-through cancer pain: A multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 9(6): 224–31 Crossref, Medline, Google ScholarFisher A, Watling M, Smith, Knight A (2010) Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers. Int J Clin Pharmacol Ther 48(12): 860–7 Crossref, Medline, Google ScholarFortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3(1): 38−44 Crossref, Medline, Google ScholarGreco MT, Corli O, Montanari M et al. (2011) Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain 27(1): 9–18 Crossref, Medline, Google ScholarKress HG (2010) Intranasal fentanyl spray for breakthrough cancer pain: an innovative approach to the unmet needs. Eur J Pain Suppl 4: 191−4 Crossref, Google ScholarPortenoy RK, Hagan NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41(3): 273–81 Crossref, Medline, Google ScholarPortenoy RK, Payne D, Jacobsen (1999) Breakthrough pain: characteristics and impact in patients with cancer. Pain 81(1–2): 129–34 Crossref, Medline, Google ScholarPortenoy RK, Burton AW, Gabrail N, Taylor D (2010) A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 151(3): 617–24 Crossref, Medline, Google ScholarTaylor D, Galan V, Weinstein S et al. (2010) Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 8(4): 184–90 Medline, Google ScholarTaylor D, Radbruch L, Revnic J et al. (2014) A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain. J Pain Symptom Manage 47(6): 1001–7 Crossref, Medline, Google ScholarTorres LM, Revnic J, Knight AD, Perelman M (2014a) Relationship between onset of pain relief and patient satisfaction with treatments for breakthrough pain in cancer. J Palliat Med 17(10): 1150–7 Crossref, Medline, Google ScholarTorres LM, Thorpe DM, Knight AD, Perelman M (2014b) Relación entre el estado de rendimiento medio con la escala ECOG y la satisfacción del paciente con el uso de fentanilo en pectina por vía nasal [In Spanish]. Revista de la Sociedad Española del Dolor 21(4): 191–6 Crossref, Google ScholarVissers D, Stam W, Nolte T, Lenre M, Jansen J (2010) Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 26(5): 1037–45 Crossref, Medline, Google ScholarZeppetella G, O'Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20(2): 87–92 Crossref, Medline, Google ScholarZeppetella G (2008) Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 35(5): 563–7 Crossref, Medline, Google ScholarZeppetella G (2009) Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care (Engl) 18(4): 331–7 Crossref, Medline, Google Scholar FiguresReferencesRelatedDetailsCited byFluorescence-enabled evaluation of nasal tract deposition and coverage of pharmaceutical formulations in a silicone nasal cast using an innovative spray deviceJournal of Advanced Research, Vol. 44 2 March 2015Volume 21Issue 3ISSN (print): 1357-6321ISSN (online): 2052-286X Metrics History Published online 27 March 2015 Published in print 2 March 2015 Information© MA Healthcare LimitedPDF download